Essity AB header image

Essity AB

ESSITY B

Equity

ISIN SE0009922164 / Valor 36851944

NASDAQ Nordic Exchange Stockholm, Equities (2025-12-23)
SEK 263.30-0.11%

Essity AB
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Essity AB is a global hygiene and health company headquartered in Sweden, known for its comprehensive range of products and solutions across various sectors. The company operates in three main business areas: Professional Hygiene, Health & Medical, and Consumer Goods. In Professional Hygiene, Essity provides sustainable hygiene management solutions, including dispensing systems for tissues, soaps, and sanitizers, as well as wiping and cleaning products tailored for commercial and public environments. The Health & Medical segment focuses on supporting patients, caregivers, and healthcare professionals with products and services in incontinence care, wound care, compression therapy, and orthopedics. In the Consumer Goods sector, Essity offers a wide array of personal and home hygiene products, such as baby care, feminine care, incontinence care, and consumer tissue products, catering to various life stages. Essity's commitment to innovation and sustainability is reflected in its diverse product offerings designed to enhance well-being and quality of life.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (11.11.2025):

Essity AB’s report for quarter 4 2024 and the full-year 2024 shows robust momentum with net sales growth and solid organic performance despite some margin pressures. In Q4 2024, net sales increased by 3.2% to SEK 37,805m with organic growth at 3.9% (volume 1.7% and price/mix 2.2%), while EBITA declined slightly by 1% to SEK 4,585m. Excluding restructuring items (IAC), EBITA improved by 2% to SEK 4,969m, though the corresponding margin experienced a minor decrease. For the full-year 2024, while net sales dipped by 1.1% to SEK 145,546m, the company delivered a significantly higher EBITA of SEK 19,475m – up 17% – and profit for the period at SEK 21,048m, alongside the Board’s proposal for a 6.5% dividend increase to SEK 8.25 per share. The report also noted notable targeted cost savings and an upcoming leadership transition as President and CEO Magnus Groth prepares to leave in 2025.

Net Sales & Organic Growth

In quarter 4 2024, Essity AB reported net sales of SEK 37,805m, an increase of 3.2% compared to the previous year, driven by an organic growth rate of 3.9% (with volume contributing 1.7% and price/mix 2.2%). Excluding restructuring, organic growth was even stronger at 4.9%.

EBITA Performance & Margins

EBITA for quarter 4 2024 decreased slightly by 1% to SEK 4,585m, while EBITA excluding IAC improved by 2% to SEK 4,969m. However, the EBITA margin excl. IAC saw a minor contraction by 0.2 percentage points, reflecting higher costs despite favorable pricing and volume effects.

Full-Year Results & Profitability

For full-year 2024, Essity AB’s net sales were SEK 145,546m (a 1.1% decrease), but they achieved a substantial EBITA increase of 17% to SEK 19,475m and recorded the highest-ever full-year profit of SEK 21,048m in total operations. Organic performance and cost-saving measures contributed significantly to these results.

Dividend Proposal & CEO Transition

The Board of Directors has proposed a dividend increase of 6.5% to SEK 8.25 per share, reflecting strong cash flow generation and a commitment to shareholder returns. Additionally, the report announced that President and CEO Magnus Groth will be leaving the company in 2025, marking a key leadership transition.

Summarized from source with an LLMView Source

Key figures

-10.6%1Y
-4.46%3Y
0.57%5Y

Performance

19.0%1Y
18.3%3Y
20.5%5Y

Volatility

Market cap

18003 M

Market cap (USD)

Daily traded volume (Shares)

649,931

Daily traded volume (Shares)

1 day high/low

297 / 293.6

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Royalty Pharma PLC
Royalty Pharma PLC Royalty Pharma PLC Valor: 55041695
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.36%USD 39.39
Encompass Health Corporation
Encompass Health Corporation Encompass Health Corporation Valor: 39085960
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.13%USD 107.23
Alkermes PLC
Alkermes PLC Alkermes PLC Valor: 13920929
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.49%USD 28.49
Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc Harmony Biosciences Holdings Inc Valor: 56295735
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.08%USD 38.44
Nano-X Imaging Ltd.
Nano-X Imaging Ltd. Nano-X Imaging Ltd. Valor: 56410599
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.91%USD 3.00
LivaNova PLC
LivaNova PLC LivaNova PLC Valor: 28726218
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.32%USD 63.25
Viking Therapeutics Inc
Viking Therapeutics Inc Viking Therapeutics Inc Valor: 24839858
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.85%USD 36.41
Cencora Inc
Cencora Inc Cencora Inc Valor: 1212868
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.16%USD 340.59
Insmed Inc
Insmed Inc Insmed Inc Valor: 12614415
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.57%USD 176.77
Globus Medical Inc
Globus Medical Inc Globus Medical Inc Valor: 18329123
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.66%USD 88.77